Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms GRID
- Sponsors Bayer; Bayer HealthCare
- 03 Dec 2021 Data was used from trials (PAZOGIST & GRID) to assess cost-effectiveness of pazopanib versus regorafenib as a third-line treatment for metastatic or unresectable gastrointestinal stromal tumors in Chinapresented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 01 May 2020 Results from NCT01103323; NCT01271712; NCT01584830; NCT01774344 evaluating Population pharmacokinetics of regorafenib in solid tumors in clinical practice considering enterohepatic circulation and food intake, published in the British Journal of Clinical Pharmacology
- 08 May 2019 This trial has been completed in Germany, according to European Clinical Trials Database.